| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/17/2010 | WO2010068788A1 Heterocyclic amides as btk inhibitors |
| 06/17/2010 | WO2010068775A2 Alkyne antagonists of lysophosphatidic acid receptors |
| 06/17/2010 | WO2010068710A2 Kinase inhibitor compounds |
| 06/17/2010 | WO2010068684A2 Methods and compositions for specific modulation of mcl-1 |
| 06/17/2010 | WO2010068437A1 Isoform specific anti-her4 antibodies |
| 06/17/2010 | WO2010068183A1 Glucose-peg conjugates for reducing glucose transport into a cell |
| 06/17/2010 | WO2010068182A1 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt |
| 06/17/2010 | WO2010068181A1 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt |
| 06/17/2010 | WO2010068130A1 Agent for treating oncological diseases using the isotope calcium-41 |
| 06/17/2010 | WO2010068037A2 Anti-cancer composition containing 4-hexylresorcinol-1,3-diol as active ingredient |
| 06/17/2010 | WO2010067888A1 Dihydropyrimidopyrimidine derivatives |
| 06/17/2010 | WO2010067886A1 Dihydropyrimidopyrimidine derivative |
| 06/17/2010 | WO2010067811A1 CONSTRUCTION OF PROTEIN-RESPONSIVE shRNA/RNAi REGULATION SYSTEM UTILIZING RNP MOTIF |
| 06/17/2010 | WO2010067671A1 Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect |
| 06/17/2010 | WO2010067617A1 Lipid membrane structure |
| 06/17/2010 | WO2010067335A1 Platinum (iv) complexes for use in the treatment of proliferative diseases such as cancer |
| 06/17/2010 | WO2010067067A1 Compounds for treating cancer |
| 06/17/2010 | WO2010067027A1 Antitumor combination combining ave8062 and docetaxel |
| 06/17/2010 | WO2010066933A1 Use of cyclosquaramide compounds as anti-tumour agents |
| 06/17/2010 | WO2010066931A1 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug |
| 06/17/2010 | WO2010066872A1 A monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (b-fn) for diagnosis or therapy |
| 06/17/2010 | WO2010066868A2 Anti-igf antibodies |
| 06/17/2010 | WO2010066858A1 Methods for the treatment and the prognosis of cancer |
| 06/17/2010 | WO2010066810A1 Transdermal pharmaceutical compositions comprising a serm |
| 06/17/2010 | WO2010066803A2 Human antibodies aganist tissue factor. |
| 06/17/2010 | WO2010066709A1 Novel pyridinyl acrylamide derivatives |
| 06/17/2010 | WO2010066239A1 Inhibitors of dimethylarginine dimethylaminohydrolase |
| 06/17/2010 | WO2010066125A1 A short peptide, preparation and uses thereof |
| 06/17/2010 | WO2010066090A1 Fusion proteins of apoptin-protein transduction domian of carboxyl-terminal end of ec-sod |
| 06/17/2010 | WO2010066046A1 Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms |
| 06/17/2010 | WO2010066018A1 Novel human endogenous retorviral erv3 variant and uses thereof for diagnosing ovarian cancer |
| 06/17/2010 | WO2010066010A1 Process for the preparation of asymmetrical bis(thiosemicarbazones) |
| 06/17/2010 | WO2010065995A1 Isolated vegf-c and vegf-d peptides and uses thereof |
| 06/17/2010 | WO2010049915A8 Poly-heteroaryl derivatives for the treatment of cancer |
| 06/17/2010 | WO2010039187A3 Fused diimidazodiazepine compounds and methods of use and manufacture thereof |
| 06/17/2010 | WO2010027458A3 Pdk inhibitor compounds and methods of use thereof |
| 06/17/2010 | WO2010025436A3 Nitrogen and sulfur-containing heterocycle derivatives |
| 06/17/2010 | WO2010025135A3 Trimeprazine and ethopropazine derivatives for promoting bone growth |
| 06/17/2010 | WO2010025050A3 Affecting bone related conditions using cd68 blocking agents |
| 06/17/2010 | WO2010022051A3 Disruptors of early/recycling endosomes |
| 06/17/2010 | WO2010007116A3 Pyridons as pdk1 inhibitors |
| 06/17/2010 | WO2009152480A3 Methods to treat solid tumors |
| 06/17/2010 | WO2009090661A9 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders |
| 06/17/2010 | WO2009060197A8 Imidazopyridazines for use as protein kinase inhibitors |
| 06/17/2010 | US20100154072 siRNA Kinase and Methods of Use |
| 06/17/2010 | US20100154071 Fxdy5 modulators for treating, diagnosing, and detecting cancer |
| 06/17/2010 | US20100152442 4-anilino quinazoline derivatives as antiproliferative agents |
| 06/17/2010 | US20100152300 Stabilized compositions of alkylating agents and methods of using same |
| 06/17/2010 | US20100152298 Present invention relates to a treatment for the management of cancer more specially the use of Flutamide anti-androgen drugsa |
| 06/17/2010 | US20100152294 Assays For Detecting Inhibitors Of Binding Between COX-2 And PDZ Proteins |
| 06/17/2010 | US20100152290 Benzo Lipoxin Analogues |
| 06/17/2010 | US20100152286 Method for Producing Fucoxanthin |
| 06/17/2010 | US20100152284 Prevention and reversal of chemotherapy-induced peripheral neuropathy |
| 06/17/2010 | US20100152271 Estrogen receptor modulators and uses thereof |
| 06/17/2010 | US20100152257 Antagonists of lysophosphatidic acid receptors |
| 06/17/2010 | US20100152256 inhibitors of the chemotaxis of chemokine ligand 1(CXCL1) induced neutrophils, polymorphonucleate and mononucleate cells, such as (2R)-2-{4-[(isopropylsulfonyl)amino]phenyl}propanamide, used for the treatment of respiratory system disorders, angiogenesis and melanoma |
| 06/17/2010 | US20100152255 Organic Compounds |
| 06/17/2010 | US20100152251 Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| 06/17/2010 | US20100152243 Treatment of renal cell carcinoma |
| 06/17/2010 | US20100152240 Pyrroline-2-one derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
| 06/17/2010 | US20100152238 Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies |
| 06/17/2010 | US20100152230 Hydroxy substituted 1h-imidazopyridines and methods |
| 06/17/2010 | US20100152218 Compositions and methods for inhibition of the jak pathway |
| 06/17/2010 | US20100152211 Inhibitors of human phosphatidylinositol 3-kinase delta |
| 06/17/2010 | US20100152206 Bicyclic Dihydropyrimidines and Uses Thereof |
| 06/17/2010 | US20100152202 Tissue Factor Promoter Polymorphisms |
| 06/17/2010 | US20100152198 Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |
| 06/17/2010 | US20100152188 Novel Heterocyclic Compounds |
| 06/17/2010 | US20100152186 Triazolyl pyridyl benzenesulfonamides |
| 06/17/2010 | US20100152184 Pharmaceutical compounds |
| 06/17/2010 | US20100152183 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| 06/17/2010 | US20100152182 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors |
| 06/17/2010 | US20100152181 Amino pyrazole compound |
| 06/17/2010 | US20100152180 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) |
| 06/17/2010 | US20100152174 Macrocyclic quinazole derivatives and their use as mtki |
| 06/17/2010 | US20100152170 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors |
| 06/17/2010 | US20100152167 Pyrimidine derivatives |
| 06/17/2010 | US20100152155 Histone Deacetylase Inhibitors |
| 06/17/2010 | US20100152154 Novel platinum compounds for treating cancer |
| 06/17/2010 | US20100152151 Tgr5 modulators and methods of use therof |
| 06/17/2010 | US20100152149 Formulation |
| 06/17/2010 | US20100152136 TP53 Gene expression and uses thereof |
| 06/17/2010 | US20100152130 Treatment of cancer with glutamine |
| 06/17/2010 | US20100152129 Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer |
| 06/17/2010 | US20100152124 Use of hederagenin 3-0 alpha-l-rhamnopyranosyl(1-2)-(beta-d-glucopyranosyl(1-4)-alpha-l-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors |
| 06/17/2010 | US20100152121 Iodo-Hexose Compounds Useful to Treat Cancer |
| 06/17/2010 | US20100152117 Aequorin-Containing Compositions and Methods of Using Same |
| 06/17/2010 | US20100152114 Antioxidant activity of GH-RH Antagonists |
| 06/17/2010 | US20100152113 Metal-binding therapeutic peptides |
| 06/17/2010 | US20100152112 Quinoline derivatives as p13 kinase inhibitors |
| 06/17/2010 | US20100152104 Methods for Inhibiting Growth of Prolactin-Responsive Cancer Cells with Cyclosporine A or Other Cyclophilin Inhibitors |
| 06/17/2010 | US20100152099 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 06/17/2010 | US20100151589 Glycoproteins Having Lipid Mobilising Properties and Therapeutic Applications Thereof |
| 06/17/2010 | US20100151051 Anti-tumor drug, medicament, composition, and use thereof |
| 06/17/2010 | US20100151037 Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound |
| 06/17/2010 | US20100151007 Compositions and methods for selective inhibition of vegf |
| 06/17/2010 | US20100151006 Cancer therapy sensitizer |
| 06/17/2010 | US20100151004 Modulation of drug sensitivity |
| 06/17/2010 | US20100151003 Egfr binding peptides and uses thereof |
| 06/17/2010 | US20100151001 Ethynylated heterodinucleoside phosphate analogs, method for the production thereof, and use thereof |